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Abstract
Background: Concerns have been raised about a potential link between the use of TNF inhibitors and development of 
malignancy in the pediatric population. We examined the worldwide experience of etanercept use in pediatric 
patients and the occurrence of malignancies as reported from clinical trials, registry studies, post-marketing 
surveillance, and published scientific literature.
Methods: All reports of "malignancy" in pediatric patients (including subjects who received etanercept before age 18 
and developed a malignancy before age 22) were collected from the etanercept clinical trials database and global 
safety database using the Medical Dictionary for Regulatory Activities (MedDRA; v12.0) standardized MedDRA query 
"Malignancies" from 1998 to August 2009. Cases were collected irrespective of treatment indication. All cases were 
included regardless of exposure to other TNF blockers or other biologics and whether the other exposure was before 
or after etanercept.
Results: A total of 18 potential malignancies were identified: 4 leukemias, 7 lymphomas, and 7 solid tumors. Three of 
the 18 malignancies remain unconfirmed. No malignancies were reported from clinical trials or the open-label 
extension studies in any indication in children.
Conclusion: The data suggest that there does not appear to be an increased risk of malignancy overall with the use of 
etanercept. Among etanercept-exposed patients aged 4 to 17 years, the estimated worldwide and US reporting rates 
for lymphoma were approximately 0.01 per 100 patient-years (1 in 10,000 pt-yrs). While the reported rate of lymphoma 
is higher in pediatric patients treated with etanercept than in normal children, the expected rate of lymphoma in 
biologic naïve JIA patients is currently unknown. The risk of TNF inhibitors in the development of malignancies in 
children and adolescents is difficult to assess because of the rarity of malignant events, the absence of knowledge of 
underlying frequency of leukemia and lymphoma in JIA, and the confounding use of concomitant immunosuppressive 
medications.
Background
Tumor necrosis factor (TNF) is a pro-inflammatory
cytokine that plays a role in host defenses and appears in
excess in various inflammatory conditions. TNF has been
suggested to play a major role in apoptosis and as an anti-
neoplastic in the immunologic response to tumor cells.
However, TNF has been shown in other experiments to
promote proliferation, invasion, and metastasis of tumor
cells [1,2]. Consequently, there is a theoretical but uncer-
tain effect of TNF inhibition on malignancy. Anti-TNF
therapies are used to treat several pediatric diseases
including juvenile idiopathic arthritis (JIA), inflammatory
bowel disease (IBD) and psoriasis (PsO).
JIA is a broad term encompassing a heterogeneous
group of persistent inflammatory arthritides in children,
including psoriatic arthritis and ankylosing spondylitis
[3]. The course of these diseases is variable with some
patients developing a progressive destructive arthritis
and others experiencing a milder course.
JIA has traditionally been treated with anti-inflamma-
tory medications such as NSAIDs, corticosteroids, meth-
otrexate, and other standard disease modifying agents.
More recently, biologic therapies such as tumor necrosis
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factor (TNF) inhibitors have been added to the treatment
armamentarium with dramatic improvement in both the
signs and symptoms of JIA as well as outcomes [4-9].
However, concerns have been raised recently about a
potential link between the use of TNF inhibitors and the
development of malignancy [10-12]. Conflicting reports
have appeared in the literature regarding the influence of
TNF inhibitors on rates of lymphomas and solid malig-
nancies in adults [1,13-18]. In addition, several case
reports have suggested the use of TNF inhibitors may be
associated with development of malignancies in children
[19,20]. The difficulty in the interpretation of the data
stems, in large part, from the low number of JIA patients,
the rarity of malignant events, and the lack of an appro-
priate comparator group of untreated JIA patients. Fur-
thermore, at certain age ranges during childhood, there is
an increased background risk to develop either leukemia
(younger ages) or lymphoma (teen years) [21,22].
One of the most commonly used TNF inhibitors to
treat JIA is etanercept, a fully human soluble receptor Fc
fusion protein that binds specifically to TNF. Etanercept
has been approved since 1999 for the treatment of polyar-
ticular course JIA in children 2 years and older [10]. Here
we present the worldwide experience of etanercept use in
pediatric patients and the occurrence of potential malig-
nancies as reported from clinical trials, registry studies,
and post-marketing surveillance over the 11-year period
from 1998 to 2009. The purpose of this communication is
to fully disclose all malignant events in pediatric patients
in the entire worldwide etanercept safety database in an
attempt to provide information for providers and
patients' families to use in their decisions about appropri-
ate JIA therapy.
Methods
All reports of "malignancy" in pediatric patients (defined
as patients who received etanercept before age 18 and
who developed a malignancy before age 22) were col-
lected from the sponsor companies' (Amgen and Wyeth
[Pfizer]) etanercept clinical trial database and global
safety database, using the Standardized Medical Diction-
ary for Regulatory Activities (MedDRA) Queries (SMQ)
version 12.0 term "Malignancies" from 1998 to 13 August
2009. The selection of the age groups was at the recom-
mendation of the US Food and Drug Administration
(FDA) and was intended to provide a follow-up observa-
tion period of at least 4 years after initiating etanercept
therapy. The search of the global safety database included
medically confirmed and unconfirmed, serious and non-
serious reports of malignancy where etanercept was iden-
tified as a suspect, co-suspect, or suspect interacting
medication. Cases were collected irrespective of treat-
ment indication and whether treatment was for an
approved or unapproved use. All cases were retrieved
independently of the reported relationship to causality,
and all cases were included regardless of exposure to
other TNF inhibitors or other biologics and regardless of
whether the exposure to these other agents occurred
before or after etanercept. The etanercept global safety
database comprises reports from "all sources", including
clinical studies (serious adverse events only), open-label
extension studies, registry studies, and spontaneous
reports (including those from consumers, healthcare pro-
fessionals, published scientific literature, other compa-
nies, and health authorities; and consumer-solicited
reports). The published scientific literature is searched
weekly using a standardized broad search strategy includ-
ing "etanercept" and adverse event terms, across biblio-
graphic databases that include ADIS Reactions, BIOSIS,
EMBASE and MEDLINE. Individual case reports are
identified involving any adverse events associated with
etanercept use. Identified cases are entered into the
global safety database regardless of the disease state or
age of the patient.
All cases were reviewed to identify those with a
reported preferred term indicating malignancy. Cases
with the following preferred terms were not considered
as reports of malignancy and were excluded: bladder cyst,
breast cyst, cyst, dermal cyst, fibrous histiocytoma, hem-
orrhagic ovarian cyst, histiocytosis hematophagic, mar-
row hyperplasia, melanocytic nevus, myelodysplastic
syndrome, neoplasm, neoplasm skin, ovarian cyst, ovar-
ian cyst ruptured, skin papilloma, and synovial cyst. The
terms "neoplasm" and "neoplasm skin" were not consid-
ered as they are defined as indicating a lesion that is a
new growth but do not necessarily imply malignancy.
Patients in whom events occur corresponding to these 2
terms and who in fact have a malignancy would be identi-
fied by the description of the specific type of malignancy.
Cases where the start of etanercept exposure occurred
after the age of 18 were not included, with the exception
of a single case where etanercept was initiated in a patient
aged 18 years and 3 months. Following medical review,
cases were grouped first by type of malignancy (leukemia,
lymphoma, solid tumor) and then by the age of the
patient at the time of diagnosis.
Etanercept exposure was estimated by using the overall
commercial market patient-years of exposure for the US
and world and applying the proportion of all etanercept
use estimated to fall in the age-groups 4 to 11; 12 to 17,
and 18 to 22 years. These age-specific proportions were
derived from US data from 2 sources: a user survey cover-
ing 1998-2002 and a commercial prescription database
for the time period from 2005-2009. Calculated estimated
US reporting rates of pediatric malignancies with etaner-
cept were compared with US incidence rates for all child-
hood malignancies as estimated by the Surveillance,
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National Cancer Institute [23], which collects and reports
cancer incidence and survival data from cancer registries
covering approximately a quarter of the US population,
including children.
Results
No malignancies have been reported to date in any of the
randomized controlled clinical trials or open-label exten-
sion trials of etanercept in pediatric patients with JIA or
psoriasis, which represents 725 patients and 1826
patient-years of exposure as of December 2009. In the
worldwide post-marketing and registry experience from
1998 to August of 2009, a total of 18 potential cases of
malignancies in pediatric or young adult patients with
etanercept exposure were identified and are described in
Table 1[5,20,24]. Identified malignancies included 4 cases
of leukemia, 7 cases of lymphoma, and 7 cases of solid
tumors among patients ranging in age from 4 to 21 years.
In 3 cases (Cases 1, 13, and 16), the reported malignan-
cies could neither be confirmed nor ruled out because of
a lack of medical history, relevant confirmatory test
r esults, and tr ea tment details. Similarly , in Case 4, the
diagnosis of lymphoma remains unconfirmed; test results
and biopsies are consistent with acute myelocytic leuke-
mia only.
In the majority of cases, patients had received one or
more concomitant medications; methotrexate was most
common (Table 1). Several patients had received other
biologic therapies besides etanercept, and in Cases 5 and
6, patients had received other TNF-inhibitor therapies for
more than a year after receiving etanercept. In addition,
several patients were treated with a number of immuno-
suppressants, including azathioprine, cyclosporine,
cyclophosphamide, mycophenolate, leflunomide, and
corticosteroids. Some of these agents have been associ-
ated with increased risk of malignancy, especially lym-
phomas [25,26].
An additional 4 cases were retrieved in the initial
search but were later excluded because the malignancy
was either pre-existing or subsequently disproven. In one
case, a 14-year old had a history of renal cell carcinoma
that preceded the use of etanercept therapy for idiopathic
pneumonia syndrome. The renal cell carcinoma disease
progression continued throughout etanercept treatment.
In a second case, acute myeloid leukemia recurrence was
reported in a 12-year old. The acute myeloid leukemia
preceded the initiation of etanercept therapy. A third case
was a report of myelodysplastic syndrome in a 17-year
old who had been receiving etanercept for juvenile arthri-
tis for 4 years, but upon medical review the adverse event
was considered to be pancytopenia due to myelosuppres-
sive therapy. The patient fully recovered with discontinu-
ation of the DMARD. Finally, follow up with the
reporting physician on a case of "possible lymphoma" in a
17-year old revealed that the initially considered diagno-
sis of lymphoma was never confirmed, and the patient
was fully recovered by August 2008.
Worldwide exposure to etanercept among pediatric
patients as of July 2009 was estimated at 49,716 patient-
years for patients 4 to 17 years old and 33,887 patient-
years for patients 18 to 22 years old. Corresponding US
exposure was estimated to be 33,409 and 22,349 patient-
years, respectively. Reporting rates for malignancies cal-
culated using these exposure estimates are listed in Table
2 .  B y  d e f i n i t i o n ,  o b s e r v e d  c a s e  c o u n t s  i n  T a b l e  2  f o r
patients with onset of malignancy at age 18 to 22 years
did not include cases with exposure after age 18, thus
only the reporting rates for the 4-to-17-year-old age
group are included for comparison with the incidence
rates in normal children. Among etanercept-exposed
patients aged 4 to 17 years, the estimated worldwide
reporting rate for all malignancies was approximately
0.02 per 100 patient-years and the estimated US report-
ing rate was slightly less at 0.015 per 100 patient-years.
Incidence rates for all malignancies from the US SEER
database (2001-2005) are 0.0119 and 0.0169 per 100 per-
son-years for the age groups of 4 to 11 and 12 to 17 years,
respectively [23]. The expected malignancy rate for all
malignancies in the normal population age group from 4
to 17 years weighted for age distribution is 0.0147 per 100
person-years. The combined rate for all malignancies
between those reported for etanercept in this age group
and the incidence in normal children are therefore in a
similar range at about 1.5 per 10,000 person-years.
Among etanercept-exposed patients aged 4 to 17 years,
the estimated worldwide and US reporting rates for lym-
phoma were approximately 0.01 per 100 patient-years (1
in 10,000 pt-yrs). Incidence rates for lymphoma in a nor-
mal pediatric population from the US SEER database
(2001-2005) are lower, but notably increase with increas-
ing age: 0.00147 per 100 person-years for ages 4 to 11 and
0.0035 per 100 person-years for ages 12 to 17 [23].
Weighted for the age distribution, the expected rate in
normal children aged 4 to 17 from the SEER database is
0.0026 per 100 pt-yrs (0.26 in 10,000 pt-yrs). The esti-
mated relative risk of lymphoma in etanercept-treated
patients in the 4-to-17-year-old age group as compared
with the healthy US population is approximately 3.8. The
expected rate of lymphoma in untreated pediatric
patients with JIA or other inflammatory conditions is
unknown.
Discussion
Concern has been raised about occurrence of malignan-
cies in pediatric patients using TNF inhibitor therapy. In
etanercept clinical trials representing 725 patients and
1826 patient-years, there have been no reported cases of
malignancy. Here we provide detail on the 18 potentialM
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Table 1: Pediatric Malignancy Cases Observed in the Worldwide Safety Database from 1998 to August 13, 2009
Case Age at malignancy 
diagnosis/Sex
Preferred term Country Length of exposure to 
ETN
Indication Confounding medications Additional comments
1 10 M Leukemia US 4 months Polyarthritis Methylprednisolone Malignancy unconfirmed
2 7 M Acute lymphocytic 
leukemia
DE "a few months" Polyarthritis MTX - 1 yr History of splenomegaly 
prior to starting etanercept
3 4 M Acute lymphocytic 
leukemia
DE 8 doses over 3 mos JIA (Still's) MTX - 6 mos
Prednisolone
Family history of cancer
4 19 M Acute myeloid 
leukemia, lymphoma
US 1.5 years Ankylosing 
spondylitis
Prednisone Lymphoma remains 
unconfirmed
Family history of cancer
5 9 M Hodgkin's lymphoma, 
Stage IV B
US ETN for 1 yr; D/C'd JIA diagnosed at 
11 mo of age
MTX - 4 yrs, Cyclosporine - 6 mo, Mycophenolate 
mofetil - 7 mo, Infliximab - 3.5 yrs
Reported in [1]
6 10 F Hodgkin's lymphoma 
stage2a
US ETN for 1 yr at age 2 JIA diagnosed at 
19 mo old
MTX - 3.7 yrs, Infliximab - 2 doses, Leflunomide - 18 
mo, Kineret - 1 mo, IV cyclophosphamide - 5 mos, 
Thalidomide - 7 mo, Rituximab - 2 doses, 
Adalimumab - 2.4 yrs
Reported in [1]
7 14 M Diffuse large Bcell 
lymphoma
DE 7 years JIA MTX
8 15 F Hodgkin's lymphoma, 
stage 2
US 4 years JIA MTX Reported in [1]
9 18 F Bcell lymphoma GB 3 years JIA MTX, azathioprine, cyclosporineM
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10 16 F Lymphomatoid 
papulosis (lymphoma)
DE 20 months from 7/2004 
to 3/2006
Vasculitis 
diagnosed in 3/
94 at age 1.5 yr
MTX 7/98-12/04, Cyclophosphamide 6/07 - 7/07, 
Azathioprine 9/07 - 11/07, Adalimumab 3/06 - 5/07, 
Infliximab 5/07 - 7/07, Rituximab 2/08- 3/08, 
Abatacept 10/08 - 11/08, Prednisolone
Lymphomatoid papulosis 
by biopsy in 2002; 
confirmed in 12/08
Lymphoma diagnosed 
2/09, unknown type 
secondary to steroid 
therapy
Off label use for "vasculitis"
11 21 F Hodgkin's lymphoma, 
stage 2a
US 3.5 years JIA diagnosed at 
age 14
MTX - 6 yrs up to 25 mg/wk Reported in [2]
12 16 M Yolk sac tumor DE 29 days JIA MTX - 5 mo Prednisone
13 17 Bladder cancer US NR NR No medical information Malignancy unconfirmed
14 18 F Papillary thyroid cancer US 4 years JIA diagnosed at 
age 10
15 18 M Thyroid cancer DE 11 months Spondylo-
arthropathy
MTX Reported in [3].
16 18 F Thyroid nodule (thyroid 
neoplasm)
GB 6 months NR but subject in 
JIA registry
MTX Thyroid nodule, 
malignancy unconfirmed
17 19 F Malignant melanoma GB 11 months Psoriatic arthritis 
diagnosed 
age 10
MTX
18 18 F Malignant melanoma GB 11 months Psoriatic 
arthritis, JIA
Pregnant; pre-existing 
pigmented nevus with 
change noted during first 
trimester of pregnancy
DE = Germany; GB = Great Britain; JIA = Juvenile idiopathic arthritis; MTX = methotrexate NR = Not Reported; US = United States
Table 1: Pediatric Malignancy Cases Observed in the Worldwide Safety Database from 1998 to August 13, 2009 (Continued)McCroskery et al. Pediatric Rheumatology 2010, 8:18
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cases of malignancy (15 documented) reported world-
wide in pediatric patients receiving etanercept over the
years from 1998 to August 2009.
Several factors make it difficult to interpret the results
of our findings. For example, assessing causality is often
difficult. It is well known that children with certain malig-
nancies, particularly leukemia, may initially present with
musculoskeletal symptoms similar to early signs of JIA
[27-29]. Studies examining the differential diagnosis of
acute lymphoblastic leukemia (ALL) and JIA have
r e v e a l e d  t h a t  s o m e  c h i l d r e n  p r e s e n t i n g  w i t h  J I A - l i k e
symptoms are later diagnosed with ALL, with a time
delay of diagnosis ranging from weeks to several months
[30,31]. Three of the four leukemia cases reported herein
(Cases 1, 2 and 3-all cases of ALL) were diagnosed within
4 months of the patients initiating etanercept therapy and
likely represent this overlap in symptomatology before
identification of the underlying malignancy.
Secondly, in adults the RA disease itself appears to pre-
dispose patients to increased rates of malignancy, partic-
ularly lymphoma and leukemia, and patients with the
highest disease severity have the most increased risk [15-
17,32-35]. Malignancy rates in adult RA patients treated
with TNF inhibitors have been evaluated in a number of
clinical trials, databases, and registries. The body of avail-
able evidence suggests that overall malignancy rates are
not increased with TNF inhibitor treatment as compared
with an RA population receiving traditional DMARDs
alone (ie, no TNF inhibitor) or with the general popula-
tion. Reported standard incidence ratios for all TNF
inhibitors combined have been in the range of 0.94 to 1.1
[36-39]. However, lymphoma risk appears to be higher in
adult RA patients using TNF-inhibitors as compared to
that of the general population, but appears to be similar
or only slightly elevated when compared with a back-
ground RA population [15,36-41]. While the safety expe-
rience with TNF inhibitors in adult RA patients may
provide some insights into the pediatric population, it is
important to note that RA and JIA are different diseases
and the association of the adult RA disease state with
increased risk for lymphoma or leukemia may or may not
translate into an increased risk in the JIA population.
The background rates of malignancies in pediatric
patients with chronic untreated JIA are not known
because malignancies are uncommon in children as a
group and because JIA itself is an uncommon disease,
although the rate of lymphoproliferative cancers in JIA in
the pediatric group has been estimated recently to be 3.8
times the rate in healthy children [42]. Long-term patient
registries adequate to measure the risk do not exist. It is
possible that chronic active inflammation in children
with JIA might also predispose to increased rates of
malignancy as suggested in adults.
Thirdly, most JIA patients are not left untreated and so
they receive concomitant therapies such as MTX or other
immunosuppressives (eg, azathioprine, cyclosporine,
cyclophosphamide) that have been associated with
increased development of malignancies [25,26]. Develop-
ment of Hodgkin's lymphoma and other malignancies in
adults with RA and children with JIA receiving MTX has
been described in several published case reports
[19,43,44], but a systematic evaluation of the risk of
malignancy in pediatric patients with JIA receiving MTX
is not available. Similarly, there is no accurate way to
assign causality in cases where many different therapies
have been used over time, including multiple DMARDs
and biologic agents (see, for example, Cases 5, 6, 9, and
10).
Finally, 4 of the 18 cases identified are questionable as 3
did not have enough information in the post-marketing
report to be able to confirm or reject the case (Cases 1,
13, and 16), and 1 other had the diagnosis of malignancy
made within 1 month of onset of therapy (Case 12). These
cases were still included in this analysis and in reporting
rate estimates.
In addition to describing the reported cases, we used
estimated etanercept exposure rates to calculate esti-
mated reporting rates for malignancies. Information on
Table 2: Estimated Reporting Rate of All Malignancies and Lymphoma per 100 Patient-years (PY) of Etanercept Exposure
4-17 years 18-22 years
Worldwide US Worldwide US
Estimated exposure to etanercept (PY) through July 2009 49,716 33,409 33,887 22,349
All malignancies (rate/100 PY) 0.020 0.015 0.024* 0.013*
Lymphoma (rate/100 PY) 0.010 0.009 0.006* 0.004*
*Calculated reporting rate for those age 18-22 years includes only cases with exposure prior to age 19 and does not includes cases with first 
etanercept exposure at age 19-22.McCroskery et al. Pediatric Rheumatology 2010, 8:18
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the age distribution of estimated etanercept exposure was
limited to U.S. information, and the proportion of expo-
sure in the youngest age groups was small; therefore, the
estimates can only be considered approximations. Other
known limitations of post-marketing surveillance data
include underreporting or stimulated reporting, surveil-
lance bias, case ascertainment, and case validation. Thus,
these reporting rates do not represent occurrence rates or
estimates of incidence rates based on observation time.
Occurrence rates are best obtained from clinical or epide-
miological studies or population registries such as SEER
where both exposure time and event number can be more
accurately ascertained. Because of these constraints, the
best estimate for malignancy rates in children from this
study is derived from the US data for the 4-to-17-year age
group. We observed 5 US cases of malignancy in 33,409
patient-years in the 4-to-17-year age group in our analy-
sis (Cases 1, 5, 6, 8, and 13; 1 confirmed lymphoma case, 2
confirmed but highly confounded lymphoma cases, and 2
unconfirmed cases [leukemia and bladder cancer]). This
is consistent with the expected total of about 5 US malig-
nancies in this age group based on age-specific data from
the US SEER database using a similarly sized population
of normal children and a similar number of years of fol-
low-up. Utilizing similar data for rates of lymphoma in
general populations of children of these ages, approxi-
mately 1 lymphoma case would have been expected
whereas our study found 3 US cases in the population of
JIA. As discussed above, the background rates of lym-
phoma in untreated JIA populations are not known. Cau-
tion should be exercised in these comparisons because of
the limitations of post-marketing surveillance data as
listed above.
None of the identified malignancies with etanercept
occurred in Crohn's disease patients, most likely because
etanercept is not approved for this indication. Other TNF
inhibitors are approved for use in this population, how-
ever, and malignancies associated with TNF inhibitor use
in pediatric patients with Crohn's disease have been
reported [45,46]. Factors involved in the development of
malignancy in patients with Crohn's disease may differ
from those in patients with JIA since children with
chronic severe Crohn's disease have a risk of developing
hepatosplenic T cell lymphoma [46]. Because the chil-
dren with the most severe cases of either JIA or Crohn's
disease are also the children most likely to be treated with
anti-TNF therapy, it is difficult to make a determination
of causality.
Conclusions
I n  s u m m a r y ,  w e  i d e n t i f i e d  1 8  p o t e n t i a l  m a l i g n a n c i e s
worldwide in pediatric and young adult patients receiving
etanercept over 11 years of experience. The development
of a malignancy following etanercept is rare, roughly 1.5
cases in 10,000 pt-yrs. The data suggest that there does
not appear to be an increased risk of malignancy overall
with the use of etanercept in children. While the reported
rate of lymphoma is higher in pediatric patients treated
with etanercept than in normal children, the expected
rate of lymphoma in JIA patients is currently unknown,
although a recent study notes that there is a significantly
elevated risk of incident lymphoproliferative cancers in
biologic-naïve JIA patients. In addition, the risk of etaner-
cept use in the development of malignancies in children
and adolescents is difficult to assess because of the low
incidence and prevalence of JIA, the rarity of malignant
events in children, the ability of some forms of malig-
nancy to present with symptoms mimicking JIA, the
absence of knowledge of the underlying frequencies of
specific malignancies in untreated JIA, and the confound-
ing use of concomitant immunosuppressive medications.
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